Glycopyrrolate

Antimuscarinic / Anticholinergic Quaternary ammonium anticholinergic

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog IV, IM, SC 0.005-0.01 mg/kg (preanesthetic); 0.01-0.02 mg/kg for bradycardia (IV) As needed; preanesthetic given 30-60 min before induction Duration: Single dose or as needed
Notes: For organophosphate toxicity: 0.01-0.02 mg/kg IV, repeat as needed to control secretions.
Cat IV, IM, SC 0.005-0.01 mg/kg (preanesthetic); 0.01-0.02 mg/kg for bradycardia (IV) As needed; preanesthetic given 30-60 min before induction Duration: Single dose or as needed
Notes: For organophosphate toxicity: 0.01-0.02 mg/kg IV, repeat as needed.
Horse IV, IM 0.005-0.01 mg/kg (preanesthetic); 0.01-0.02 mg/kg for bradycardia (IV) As needed Duration: Single dose or as needed
Notes: For organophosphate toxicity: 0.01-0.02 mg/kg IV, repeat as needed.
Cattle IV, IM 0.005-0.01 mg/kg (preanesthetic); 0.01-0.02 mg/kg for bradycardia (IV) As needed Duration: Single dose or as needed
Notes: For organophosphate toxicity: 0.01-0.02 mg/kg IV, repeat as needed.
Small Ruminants (sheep, goats) IV, IM 0.005-0.01 mg/kg (preanesthetic); 0.01-0.02 mg/kg for bradycardia (IV) As needed Duration: Single dose or as needed
Notes: For organophosphate toxicity: 0.01-0.02 mg/kg IV, repeat as needed.
Rabbit IV, IM, SC 0.01-0.02 mg/kg (preanesthetic) Single dose Duration: Single dose
Notes: Use with caution due to risk of gastrointestinal stasis.
Birds (e.g., psittacines) IM 0.01-0.02 mg/kg (preanesthetic) Single dose Duration: Single dose
Notes: Limited data; use with caution.
Exotic small mammals (ferrets, guinea pigs) IM, SC 0.01-0.02 mg/kg (preanesthetic) Single dose Duration: Single dose
Notes: Use with caution in species prone to ileus.

Clinical Indications & Species Uses

General Indications
  • Reduction of salivary, tracheobronchial, and pharyngeal secretions during anesthesia
  • Prevention or treatment of bradycardia during anesthesia or surgery
  • Adjunct in the management of peptic ulcer disease
  • Antidote for organophosphate or carbamate toxicity (in combination with pralidoxime)
Dog (Canine)
  • Preanesthetic medication to reduce secretions and prevent bradycardia
  • Adjunct in the treatment of bradyarrhythmias (e.g., sinus bradycardia, atrioventricular block)
  • Reduction of gastrointestinal motility in cases of diarrhea or spasms
  • Treatment of peptic ulcer disease (as adjunct to reduce gastric acid secretion)
  • Antidote for organophosphate toxicity (in combination with pralidoxime)
Cat (Feline)
  • Preanesthetic medication to reduce secretions and prevent bradycardia
  • Adjunct in the treatment of bradyarrhythmias
  • Reduction of gastrointestinal motility
  • Treatment of peptic ulcer disease (as adjunct)
  • Antidote for organophosphate toxicity
Horse (Equine)
  • Preanesthetic medication to reduce secretions and prevent bradycardia
  • Treatment of bradyarrhythmias (e.g., second-degree AV block)
  • Reduction of gastrointestinal spasms (e.g., in colic)
  • Antidote for organophosphate toxicity
Cattle (Bovine)
  • Preanesthetic medication to reduce secretions and prevent bradycardia
  • Treatment of bradyarrhythmias
  • Reduction of gastrointestinal motility (e.g., in diarrhea)
  • Antidote for organophosphate toxicity
Small Ruminants (Sheep / Goat)
  • Preanesthetic medication to reduce secretions and prevent bradycardia
  • Treatment of bradyarrhythmias
  • Reduction of gastrointestinal motility
  • Antidote for organophosphate toxicity
Rabbit & Small Mammals
  • Preanesthetic medication to reduce secretions and prevent bradycardia
  • Reduction of gastrointestinal motility (use with caution due to risk of ileus)
Avian & Poultry
  • Preanesthetic medication to reduce secretions (limited use)
  • Antidote for organophosphate toxicity (off-label)
Exotic & Other Species
  • Preanesthetic medication in small mammals (e.g., ferrets, guinea pigs) to reduce secretions
  • Antidote for organophosphate toxicity in various species

Pharmacology & Mechanism of Action

Drug Class: Antimuscarinic / Anticholinergic | Pharmacological Group: Quaternary ammonium anticholinergic

Mechanism of Action: Glycopyrrolate is a quaternary ammonium antimuscarinic agent that competitively antagonizes acetylcholine at muscarinic receptors, thereby blocking the effects of parasympathetic nerve stimulation. It does not cross the blood-brain barrier significantly, so its effects are primarily peripheral. It reduces secretions (salivary, tracheobronchial, gastric), inhibits gastrointestinal motility, and produces mydriasis and cycloplegia when applied topically to the eye. It also blocks vagal reflexes, leading to an increase in heart rate.

Pharmacodynamics: Glycopyrrolate produces a dose-dependent inhibition of muscarinic receptor-mediated responses. It effectively reduces salivary and respiratory tract secretions, decreases gastric acid secretion and gastrointestinal motility, and prevents bradycardia during anesthesia. Its onset of action after IV administration is rapid (within 1 minute), and the duration of effect is longer than atropine, typically lasting 2-3 hours. It has minimal central nervous system effects due to its quaternary ammonium structure, which limits its penetration of the blood-brain barrier.

⚡ Pharmacokinetics Summary

Absorption: Glycopyrrolate is poorly absorbed from the gastrointestinal tract; oral bioavailability is low (approximately 10-20%). After oral administration, peak plasma concentrations occur within 1-2 hours. Parenteral administration (IV, IM, SC) results in rapid absorption and onset of action.
Distribution: As a quaternary ammonium compound, glycopyrrolate is ionized at physiological pH and does not readily cross lipid membranes, including the blood-brain barrier and placenta. It distributes mainly in extracellular fluids. The volume of distribution is relatively small. It does not accumulate in tissues.
Metabolism: Glycopyrrolate undergoes minimal hepatic metabolism. The majority of the drug is excreted unchanged in the urine. Some biliary excretion may occur.
Excretion: Glycopyrrolate is primarily eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion. Renal clearance is high. In animals with renal impairment, elimination may be prolonged, requiring dose adjustment.
Half-Life: The elimination half-life in dogs is approximately 0.6-1.2 hours after IV administration. In horses, the half-life is about 1.5 hours. In humans, it is around 0.7-1.0 hours.
Bioavailability: Oral bioavailability is low (10-20%) due to poor absorption. Parenteral administration provides complete bioavailability.
Protein Binding: Protein binding is low, approximately 10-20%.

Available Formulations & Strengths

Injectable Solution 0.2 mg/mL (1 mL, 2 mL, 5 mL vials) (IV, IM, SC)
Oral Tablet 1 mg, 2 mg (PO)
Oral Solution 0.5 mg/5 mL (PO)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to glycopyrrolate or other anticholinergics
  • Tachycardia or tachyarrhythmias
  • Glaucoma
  • Obstructive gastrointestinal disease (e.g., pyloric stenosis, ileus)
  • Obstructive uropathy (e.g., urethral obstruction)
  • Myasthenia gravis (unless used with anticholinesterase agents)
  • Severe renal impairment (use with caution, dose adjustment may be needed)
Warnings & Clinical Precautions:
  • Use with caution in animals with cardiovascular disease, especially those prone to arrhythmias.
  • May cause constipation and urinary retention, especially in older animals.
  • In herbivores (horses, rabbits, ruminants), anticholinergics can cause gastrointestinal stasis and colic; use with extreme caution.
  • May cause hyperthermia due to decreased sweating (in species that sweat) or impaired heat dissipation.
  • Use with caution in animals with fever or in hot environments.
  • In animals with renal impairment, reduce dose or increase dosing interval.
  • May cause mydriasis and cycloplegia if accidentally applied to the eye.
  • In organophosphate toxicity, use in combination with pralidoxime; glycopyrrolate alone does not reactivate cholinesterase.
  • Do not use as a sole treatment for organophosphate toxicity; always combine with pralidoxime.
  • In neonates and geriatric animals, use with caution due to increased sensitivity to anticholinergic effects.

Adverse Effects & Reactions

Common:

  • Dry mouth
  • Mydriasis
  • Tachycardia
  • Constipation
  • Urinary retention
  • Decreased gastrointestinal motility
  • Injection site reactions (if IM/SC)

Serious / Severe:

  • Severe tachycardia or arrhythmias
  • Ileus or gastrointestinal stasis (especially in herbivores)
  • Hyperthermia
  • Central nervous system excitation (rare, but possible in young animals)
  • Respiratory depression (at high doses)

Rare:

  • Hypersensitivity reactions (urticaria, anaphylaxis)
  • Paralytic ileus
  • Acute angle-closure glaucoma
  • Psychosis or confusion (in animals with compromised blood-brain barrier)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Other anticholinergics (e.g., atropine, scopolamine) Additive anticholinergic effects, increased risk of toxicity. High
Potassium chloride (oral) Anticholinergics may increase the risk of gastrointestinal mucosal lesions from oral potassium chloride. Moderate
Digoxin Anticholinergics may increase digoxin absorption due to decreased gastrointestinal motility. Moderate
Phenothiazines (e.g., acepromazine) May enhance anticholinergic effects; increased risk of tachycardia and hypotension. Moderate
Tricyclic antidepressants (e.g., amitriptyline) Additive anticholinergic effects. Moderate
Antihistamines (e.g., diphenhydramine) Additive anticholinergic effects. Moderate
Cholinesterase inhibitors (e.g., neostigmine, pyridostigmine) Antagonistic effects; glycopyrrolate can reverse the muscarinic effects of cholinesterase inhibitors. Moderate
Ketoconazole May increase plasma concentrations of glycopyrrolate (theoretical). Mild

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe tachycardia
  • Hypertension
  • Hyperthermia
  • Dry mucous membranes
  • Mydriasis
  • Ileus
  • Urinary retention
  • CNS excitation (agitation, seizures) in severe cases
  • Respiratory depression

Emergency Treatment Protocol: Treatment is primarily supportive. Discontinue the drug. Administer activated charcoal if oral ingestion occurred recently. For severe anticholinergic effects, physostigmine (0.02-0.04 mg/kg IV in dogs) may be used as an antidote, but should be used with caution due to risk of cholinergic crisis. Supportive care includes cooling for hyperthermia, fluid therapy for hypotension, and cardiac monitoring. In cases of severe tachycardia, beta-blockers (e.g., propranolol) may be considered. Seizures may be treated with diazepam or barbiturates. Ensure adequate ventilation and oxygenation.

Food Animal Withdrawal Times

🥩 Meat: 0 days🥛 Milk: 0 days🥚 Eggs: 0 days

Glycopyrrolate is not approved for use in food animals in many countries. Withdrawal times are not established. In the US, extra-label use in food animals requires a withdrawal period determined by a veterinarian, but due to the short half-life, a withdrawal time of 0 days is often used. However, it is essential to consult regulatory authorities and follow local regulations.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F).

Handling & Special Conditions: Protect from freezing. Keep container tightly closed. Store in a dry place.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use. However, it is widely used in veterinary medicine as an extra-label drug.

Extra-Label (Off-Label) Use: In the US, glycopyrrolate is not FDA-approved for veterinary use, but it is commonly used extra-label in animals. Under AMDUCA, extra-label use is permitted by or on the order of a veterinarian within the context of a valid veterinarian-client-patient relationship. For food animals, a withdrawal time must be assigned by the veterinarian, and the drug must not be used in an extra-label manner if it results in violative residues.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Glycopyrrolate is a valuable anticholinergic agent in veterinary anesthesia and emergency medicine. Its quaternary ammonium structure provides a longer duration of action and fewer central nervous system effects compared to atropine. It is particularly useful for reducing secretions and preventing bradycardia during anesthesia. In cases of organophosphate toxicity, it is preferred over atropine because it does not cross the blood-brain barrier, allowing for peripheral muscarinic blockade without exacerbating central signs. However, it must be used with caution in herbivores due to the risk of gastrointestinal stasis and colic. Dosing should be individualized based on the species and clinical situation. Always monitor heart rate, respiratory rate, and body temperature during use. For food animals, ensure compliance with withdrawal times and regulatory requirements.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)